CLEVELAND, June 11, 2012 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced Pharm-Olam International (POI), a global Contract Research Organization (CRO), signed a multi-year, multi-million dollar contract standardizing on the cloud-based unified clinical research platform, DATATRAK ONE™. Already a CRO Connect Partner™ designing their own trials, Pharm-Olam licensed the use of multiple DATATRAK ONE™ products – uDesign, uIRT, uEDC and uTrain.
"Pharm-Olam continues to adopt new technologies to provide value across the clinical research process," said John Hovre, COO, at Pharm-Olam. "The expansion of our partnership positions Pharm-Olam to offer sponsors more dynamic, integrated data solutions for full service and functional outsourcing."
"I am especially proud to announce the signing of this agreement," stated Laurence P. Birch, DATATRAK's Chairman of the Board and CEO. "POI is a long-term client committed to another five years. This partnership is a testament to the superiority of DATATRAK's technology and services delivery. We look forward to continuing to deliver the most user-friendly, powerful clinical research platform in support of Pharm-Olam's delivery of clinical trials."
About Pharm-Olam International
Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, POI focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines. For more information, visit http://pharm-olam.com.
DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services™ group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I - Phase IV drug and devices studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit http://www.datatrak.net.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's quarterly report filed with the OTCQX Market on May 10, 2012 announcing its results for the three-month period ending March 31, 2012. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
SOURCE DATATRAK International, Inc.